Zhichao Yin
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Safety, pharmacokinetics and population pharmacokinetic model of TQH2722, a novel IL-4Rα monoclonal antibody in healthy subjects: a phase I, first-in-human, single-dose and multiple-dose escalation study.
Journal: Journal of pharmaceutical sciences
Published: January 10, 2025
Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation.
Journal: Haematologica
Published: August 28, 2024
CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis.
Journal: Cancer reports (Hoboken, N.J.)
Published: October 05, 2021
Quick identification of target antigens by tissue flow cytometry for CAR-T therapy in B-cell malignancies.
Journal: Cytometry. Part B, Clinical cytometry
Published: September 09, 2021
CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 22, 2021
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Journal: American journal of hematology
Published: December 31, 2020
Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia.
Journal: Blood cancer journal
Published: September 15, 2019
Childhood familial environment and adulthood depression: evidence from a Chinese population-based study.
Journal: International health
Published: March 16, 2019
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
Journal: Leukemia
Published: January 30, 2019
Last Updated: 09/26/2026